Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Public Health, Environmental and Occupational Health,Pharmacology, Toxicology and Pharmaceutics (miscellaneous)
Reference46 articles.
1. Siden EG, Park JJ, Zoratti MJ, et al. Reporting of master protocols towards a standardized approach: a systematic review. Contemp Clin Trials Commun. 2019;15: 100406. https://doi.org/10.1016/j.conctc.2019.100406.
2. Woodcock J, LaVange LM. Master protocols to study multiple therapies, multiple diseases, or both. N Engl J Med. 2017;377(1):62–70. https://doi.org/10.1056/NEJMra1510062.
3. Food and Drug Administration, U.S. Department of Health and Human Services. Master protocols: efficient clinical trial design strategies to expedite development of oncology drugs and biologics—guidance for industry 2018.
4. Lu CC, Li XN, Broglio K, et al. Practical considerations and recommendations for master protocol framework: basket, umbrella and platform trials. Ther Innov Regul Sci. 2021. https://doi.org/10.1007/s43441-021-00315-7
5. Ren Y, Li X, Chen C. Statistical considerations of phase 3 umbrella trials allowing adding one treatment arm mid-trial. Contemp Clin Trials. 2021;109:106538. https://doi.org/10.1016/j.cct.2021.106538
Cited by
9 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献